Professional background
Ms MacDonald is a consultant gynaecological oncologist and the clinical lead for gynaecological oncology at UCLH. She leads the regional Teenage and Young Adult gynaecological oncology service, and is the North Central London Cancer Alliance network clinical director for gynaecological oncology.
Ms MacDonald qualified at St Mary's Hospital Medical School in 1994. She trained in obstetrics and gynaecology in North West Thames and undertook a research MD at St Bartholomew's Hospital. She completed her sub-specialty training in gynaecological oncology at UCLH and became a consultant in 2006.
Research interests
Malignant germ cell tumours, ovarian cancer, post-treatment effects and cancer screening.
Publications
Barrett JE, Jones A, Evans I, Herzog C, Reisel D, Olaitan A, Mould T, MacDonald N, Doufekas K, Newton C, Crosbie EJ, Bjørge L, Colombo N, Dostalek L, Costas L, Peremiquel-Trillas P, Ponce J, Matias-Guiu X, Zikan M, Cibula D, Wang J, Sundström K, Dillner J, Widschwendter M (2023). The WID-EC test for the detection and risk prediction of endometrial cancer. Int J Cancer. May 1;152(9):1977-1988.
Graham R, MacDonald ND, Lockley M, Miller R, Butler J, Murali K, et al (2022). Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort study. Eur J Obstet Gynecol Reprod Biol. 271:138-44.
Graham R, Stoneham S, Lockley M, MacDonald ND. (2022). Letter to Editor in response to: Controlled aspiration of large paediatric ovarian cystic tumors. J Pediatr Surg. Aug 12:S0022-3468(22)00511-5. doi: 10.1016/j.jpedsurg.2022.08.007. Online ahead of print.
Wong M, Eaton PK, Zanichelli C, Moore C, Hegarty C, MacDonald N. (2021). The prevalence of undiagnosed postoperative lower limb lymphedema among gynecological oncology patients. Eur J Surg Oncol. Dec 29:S074.
Lewin J, Wilkinson N, MacDonald N, Kotsopoulos IC and Olaitan A (2021). Female genital tract melanoma:10 years of experience at a single tertiary centre. J Low Genit Tract Dis. Apr 1;25(2):142-145.
Kasivisvanathan, V, Lindsay J, Rakshani-Moghadam S, Elhamshary A, Kapriniotis K…MacDonald N et al (2020). A cohort study of 30-day mortality after non-emergency surgery in a COVID-19 cold site. Int J Surg 84;57-65.
Turkgeldi L, Cutner A, Turkgeldi E, Al Chami A, Cassoni, MacDonald N et al (2019). Laparoscopic Ovarian Transposition and Ovariopexy for Fertility Preservation in Patients Treated with Pelvic Radiotherapy with or without Chemotherapy Facts Views Vis Obgyn 11 (3): 235-242.
Marchetti C, Kristeleit R, McCormack M, Mould T, Olaitan A, Widschwendter M, MacDonald N, Ledermann JA. (2017). Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review. Gynecol Oncol. Jan;144(1):57-60
Milani A, Kristeleit R, McCormack M, Raja F, Luvero D, Widschwendter M, MacDonald N et al (2017). Switching from standard to dose dense chemotherapy in front line treatment of advanced ovarian cancer: A retrospective study of feasibility and efficacy. ESMO Open Jan 31;1(16)
Luz R, MacDonald N, Mould T. (2016). Omental biopsy for surgical staging of uterine serous carcinoma. Int J Gynecol Cancer Oct; 26(8):1448-54
Doufekas K, Zheng SC, Ghazali S, Wong M, Mohamed Y, Jones A, Reisel D, Mould T, Olaitan A, MacDonald N et al (2016). DNA methylation signatures in vaginal fluid samples for detection of cervical and endometrial cancer. Int J Gynecol Cancer Jun 2. doi: 10.1097/IGC.0000000000000739 [Epub ahead of print].
Lemech CR, Ensell L, Paterson JC, Eminowicz G, Lowe H, Arora R, Arkenau HT, Widschwendter M, MacDonald N et al (2016). Enumeration and molecular characterisation of circulating tumour cells in endometrial cancer. Oncology 91(1):48-54.
Doufekas K, Hadwin R, Kandimalla R, Jones A, Mould T, Crowe S, Olaitan A, MacDonald N, et al (2013). GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer. Int J Gynecol Cancer Jul;23(6):1050-5.
Hersheson J, Mencacci NE, Davis M, MacDonald N, Trabzuni D, et al. (2013). Mutations in the Autoregulatory Domain of β-Tubulin 4a Cause Hereditary Dystonia. Ann Neurol. 2013 Apr; 73(4): 546–553.
Saha A, Varughese M, Gallagher CJ, Orphanos G, Wilson P, Oram D, Jeyarajah A, Reynolds K, Shepherd J, McCormack M, Olaitan A, MacDonald N, Mould T, McNeish I, Ledermann JA (2012). Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery. Int J Gynecol Cancer May;22(4):566-72.
O'Gorman T, MacDonald N, Mould T, Cutner A, Hurley R, Olaitan A. (2009). Total laparoscopic hysterectomy in morbidly obese women with endometrial cancer anaesthetic and surgical complications. Eur J Gynaecol Oncol. 30(2):171-3.
Salvesen H.B, Kumar R, Stefansson I, Angelini S, MacDonald N, Smeds J, Jacobs I.J, Hemminki K, Das S, Akslen L.A (2005). Low frequency of BRAF and CDKN2A mutations in endometrial cancer. Int J Cancer 115(6):930-4.
Menon U, Skates S.J, Lewis S, Rosenthal A.N, Rufford B, Sibley K, MacDonald N, Dawnay A, Jeyarajah A, Bast RC Jr, Oram D, Jacobs I.J (2005). Prospective study using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer. J Clin Oncol 23(31):7919-26.
MacDonald N.D, Salvesen H.B, Ryan A, Malatos S, Stefansson I, Iversen O.E, Akslen L.A, Das S, Jacobs I.J. (2004). Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series. Int J Gynecol Cancer 14 (5):957-65.
Salvesen H.B, Stefansson I, Kretzschmar E.I, Gruber P, MacDonald N.D, Ryan A, Jacobs I.J, Akslen L.A, Das S (2004). Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol Dec;25(6):1615-23.
Skates S.J, Menon U, MacDonald N, Rosenthal A.N, Oram D.H, Knapp R.C, Jacobs I.J. (2003) Calculation of the Risk of Ovarian Cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 21 (10 Suppl):206-10.
Halford S.E, Sawyer E.J, Lambros M.B, Gorman P, MacDonald N.D, Talbot I.C, Foulkes W.D, Gillett C.E, Barnes D.M, Akslen L.A, Lee K, Jacobs I.J, Hanby A.M, Ganesan T.S, Salvesen H.B, Bodmer W.F, Tomlinson I.P, Roylance R.R. (2003). MSI-low, a real phenomenon which varies in frequency among cancer types. J Pathol 201(3):389-94.
Alexander-Sefre F, Salvesen H.B, Ryan A, Singh N, Akslen L.A, MacDonald N, Wilbanks G, Jacobs I.J. (2003) Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis. Gynecol Oncol 91(1):218-25.
Stefansson I, Akslen L.A, MacDonald N, Ryan A, Das S, Jacobs I.J, Salvesen H.B. (2002). Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clin Cancer Res 8(1):138-43.
Salvesen H.B, MacDonald N, Ryan A, Jacobs I.J, Lynch E.D, Akslen L.A, Das S. (2001). PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 91(1):22-6.
Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J. et al. (2001). Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56(12):1702-6.
MacDonald N, Menon U, Jacobs I, (2000). Registration of ovarian cancer in England and Wales. Br J Cancer Jul; 83(2): 279.
MacDonald N.D, Salvesen H.B, Ryan A, Iversen O.E, Akslen L.A, Jacobs I.J. (2000). Frequency and prognostic impact of microsatellite instability in a population-based study of 259 endometrial carcinomas. Cancer Research 60(6):1750-2.
Salvesen H.B, MacDonald N, Ryan A, Iversen O.E, Jacobs I.J, Akslen L.A, Das S. (2000). Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 6(9):3607-13.
Jacobs I, Skates S, MacDonald N. (2000) Ovarian cancer screening was feasible but did not decrease incidence of index cancer or mortality. West J Med. 172(2):97.
Menon U, Talaat A, Rosenthal AN, MacDonald N, Jeyarajah A, Skates S, Sibley K, Oram DH, Jacobs IJ.n(2000). Performance of ultrasound as a second-line test to serum CA 125 in ovarian cancer screening. BJOG 107(2):165-9.
MacDonald N, Sibley K, Rosenthal A.N, Menon U, Jeyarajah A, Oram D, Jacobs I.J. (1999). A comparison of national cancer registry and direct follow-up in the ascertainment of ovarian and fallopian tube cancer. British Journal of Cancer 80(11):1826-7.
Jacobs I.J, Skates S, MacDonald N, Menon U, Rosenthal A, Prys-Davies A, Woolas R, Jeyarajah A, Sibley K, Oram D.H. (1999). Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353:1207-10.
Jeyarajah A, Ind T.J, MacDonald N, Skates S.J, Oram D.H, Jacobs I.J. (1999) Increased mortality in postmenopausal women with serum CA 125 elevation. Gynecol Oncol 73:242-6.
Menon U, Talaat A, Jeyarajah A, Rosenthal A, MacDonald N.D, Skates S, Sibley K, Oram D, Jacobs I.J. (1999) Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA 125 elevation. B J Cancer 80(10):1644-7.